INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 414m ago
HOUSE PTR13m ago
SEC 13F13m ago
ROBINHOOD CHAIN13m ago
SEC FORM 4/Option exerciseVerified data

Pershing Edward reported PVCT

Director, CEO, 10% Owner · PROVECTUS BIOPHARMACEUTICALS, INC. · PROVECTUS BIOPHARMACEUTICALS, INC. — Series D-1 Convertible Preferred Stock

Side
M
Value
—
Shares
7,599
Price
—
Executed
Oct 23, 2026
Disclosed
Oct 23, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Oct 23 executedOct 23, 2026 disclosed

PVCT · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · 0.3% of prior position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · PVCT

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    8
    PE
    Pershing EdwardDirector, CEO, 10% Owner
    PVCTPROVECTUS BIOPHARMACEUTICALS, INC.
    Option exercise
    		M—Oct 23, 2026Oct 23, 2026
    traded Oct 23, 2026
    		+0dSEC FORM 4

    Evidence

    8
    PE
    Pershing EdwardDirector, CEO
    PVCTPROVECTUS BIOPHARMACEUTICALS, INC.
    Grant or award
    		A—Nov 26, 2025Nov 28, 2025
    traded Nov 26, 2025
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001493152-26-048321
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Oct 23, 2026
    Published
    Oct 23, 2026
    Ingested by INSIDER
    Nov 5, 02:09 UTC
    Last re-read
    Nov 5, 02:09 UTC

    Extracted facts

    Filer
    Pershing Edward
    Role
    Director, CEO, 10% Owner
    Transaction
    Option exerciseAs filed: “M”
    Asset
    PROVECTUS BIOPHARMACEUTICALS, INC. — Series D-1 Convertible Preferred Stock
    Ticker
    PVCT
    Shares
    7,599
    Price per share
    $0
    Execution date (reported)
    Oct 23, 2026
    Owned after transaction
    3.01M shares
    Days from execution to publication
    0

    What this establishes

    Pershing Edward filed this Form 4 reporting a option exercise of PVCT on Oct 23, 2026. It became public on Oct 23, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, CEO, 10% Owner
    Pershing Edwardcik:0001689739
    Issuer
    PROVECTUS BIOPHARMACEUTICALS, INC.cik:0000315545

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.